Want to see NIKI full AI Analyst Report?
NIKI Stock Chart & Stats
$7.90
-$0.20(-2.33%)
At close: 4:00 PM EDT
$7.90
-$0.20(-2.33%)
Day’s Range― - ―
52-Week Range$1.70 - $17.20
Previous CloseN/A
Volume50.61K
Average Volume (3M)26.49K
Market Cap
$5.52M
Enterprise Value-$2.15M
Total Cash (Recent Filing)$3.45M
Total Debt (Recent Filing)$3.44M
Price to Earnings (P/E)―
Beta1.71
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,938,625
10 Day Avg. Volume17,049
30 Day Avg. Volume26,492
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-4.24
Enterprise Value/Market Cap-0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda2.61
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet ResilienceModerate leverage and a sizable equity base provide a financial buffer while the company develops its biotech and diagnostics activities. Although losses continue, this cushion may preserve strategic flexibility and help support operations through commercialization efforts over the next several quarters.
Diagnostics Platform And Market OpportunityThe licensed laboratory infrastructure and proprietary biomarker platforms give Niki a defined foundation in non-invasive neurodiagnostics. Alzheimer’s testing, rare disease, and neuro-oncology applications could provide multiple routes to product and service expansion if the pipeline achieves broader clinical and commercial adoption.
Nasdaq Compliance RestoredRestored Nasdaq bid-price compliance removes the immediate delisting issue described in the article and helps preserve the company’s public-market access. Continued listing supports visibility, financing flexibility, and the ability to use equity markets while management advances the post-merger business plan.
Bears Say
Commercial Scale Remains WeakNear-zero recent revenue and sustained operating losses indicate that the business has not yet reached meaningful commercial scale. Without stronger recurring sales, the company has limited internal funding capacity and remains dependent on future execution to convert its diagnostic and biotech activities into durable revenue.
Persistent Cash BurnContinuous negative operating and free cash flow shows that core activities have not funded themselves across the reported period. Even with some improvement in 2024–2025, ongoing burn can consume financial resources and force reliance on external capital, limiting flexibility for development and growth investments.
Potential Equity Financing DilutionThe at-the-market facility provides financing flexibility, but any share sales would raise capital by issuing common stock rather than through operating cash generation. That approach can dilute existing holders and underscores the company’s need to access external funding while revenue and cash flow remain weak.
Niki BioSolutions Inc News
NIKI FAQ
What was Niki BioSolutions Inc’s price range in the past 12 months?
Niki BioSolutions Inc lowest stock price was $1.70 and its highest was $17.20 in the past 12 months.
What is Niki BioSolutions Inc’s market cap?
Niki BioSolutions Inc’s market cap is $5.52M.
When is Niki BioSolutions Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Niki BioSolutions Inc’s earnings last quarter?
Currently, no data Available
Is Niki BioSolutions Inc overvalued?
According to Wall Street analysts Niki BioSolutions Inc’s price is currently Overvalued.
Does Niki BioSolutions Inc pay dividends?
Niki BioSolutions Inc does not currently pay dividends.
What is Niki BioSolutions Inc’s EPS estimate?
Niki BioSolutions Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Niki BioSolutions Inc have?
Niki BioSolutions Inc has 2,938,625 shares outstanding.
What happened to Niki BioSolutions Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Niki BioSolutions Inc?
Currently, no hedge funds are holding shares in NIKI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Niki BioSolutions Inc
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.22% Other Institutional Investors
99.78% Public Companies and
Individual Investors